Gilead Sciences | Le Bénéfice D'Exploitation



Operating Profit Changement Date
AbbVie USD -1490000000 5.32B 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
ALKERMES USD 162.69M 57.93M 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Amgen USD 2.31B 182M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
Glaxosmithkline GBP 702M 513M 2024-12
Incyte USD 301.51M 155.43M 2024-12
J&J USD 3.89B 549M 2024-12
Merck USD 4.3B 369M 2024-12
Moderna USD -1246000000 1.18B 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Pfizer USD -409000000 5.57B 2024-12
PTC Therapeutics USD -62489000 7.98M 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Sanofi EUR 4.09B 1.81B 2024-09
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
United Therapeutics USD 357.7M 14.6M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Gilead Sciences Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.